Raised $120 million in a convertible personal debt offering. Generated $6.0 million in operating cash flow and ended quarter with $134.5 million in cash and cash equivalents. Obtained AVR, a innovator in the over-the-counter dry eye market. Acquired three products with a mixed brand/generic annual market size of $20 million. Filed four new internally developed ANDAs with a mixed annual marketplace size of $190 million. Received FDA approval for injectable Levofloxacin 25mg/mL single-make use of vials. Consolidated income for the second quarter of 2011 was $32.1 million, up 59 percent over the comparable prior year quarter consolidated revenue of $20.2 million. The increase in revenue was the consequence of partial one fourth AVR sales totaling $3.7 million, the continued growth of products launched in 2010 2010, strong organic growth in founded injectable and ophthalmic products and an increase in seasonal allergy ophthalmic product sales.Related StoriesResearchers reconstruct ancient virus to improve gene therapy3D printed model of fetus face helps determine life-threatening airway mass in unborn childNew computer program can predict cochlear implant outcomes in hearing-impaired childrenThe panel found consistent literature of benefit of medical procedures of NVC, however the evidence relied on uncontrolled studies mostly. The panel generally agreed on the anatomic and practical features define the distinct clinical entity of NVC and that it’s best evaluated with history and physical exam results. Endoscopy and photography are useful however, not routinely indicated always, while radiographic studies are not felt to become useful in analyzing NVC.